<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="23214">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01687413</url>
  </required_header>
  <id_info>
    <org_study_id>201207059</org_study_id>
    <nct_id>NCT01687413</nct_id>
  </id_info>
  <brief_title>Post Operative Adjuvant Therapy De-intensification Trial for Human Papillomavirus-related, p16+ Oropharynx Cancer</brief_title>
  <acronym>ADEPT</acronym>
  <official_title>Adjuvant De-escalation, Extracapsular Spread, P16+, Transoral (A.D.E.P.T.) Trial for Oropharynx Malignancy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized clinical trial studies the intensity of adjuvant (&quot;helper&quot;) therapy required
      in p16 positive oropharynx cancer patients, who have had all known disease removed
      surgically by a minimally  invasive approach, and who have extracapsular spread in their
      lymph nodes. After the surgery, patients are randomized to receive either radiation alone,
      or radiation and weekly cis-platinum during therapy. Patients are then followed for cancer,
      functional and quality of life outcomes.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Disease-free survival (DFS)</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Survival probability will be estimated by Kaplan-Meier analysis and survival curves for patients with adjuvant radiotherapy w and w/o chemotherapy will be compared by use of log-rank statistic.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Locoregional control</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Rate of patients with no recurrence at original oropharyngeal site or in the neck nodal basins.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Distant metastasis rates</measure>
    <time_frame>Up to 5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assessed by biopsy or imaging-detected recurrent disease at sites away from the original primary and cervical zone.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease specific survival</measure>
    <time_frame>Up to 5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Defined as time from surgery to death from recurrent oropharyngeal cancer or treatment-related death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of complications/acute toxicity</measure>
    <time_frame>4.5 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Function and quality of life (QOL)</measure>
    <time_frame>Up to 24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Multiplicity corrected tests for trend (i.e., non-parametric Jonckehere-Terpstra test) used to compare patients with adjuvant radiotherapy w/ and w/o chemotherapy at single time points (study entry 1, 3, 6, 12 and 24 months).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">496</enrollment>
  <condition>Oropharyngeal Neoplasms</condition>
  <arm_group>
    <arm_group_label>Radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo postoperative IMRT once daily, 5 days a week, for 6 weeks.  The prescribed radiotherapy dose will be 60 Gy in 2 Gy once-daily fraction size (total of 30 fractions)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Radiotherapy, cisplatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients undergo postoperative IMRT once daily, 5 days a week, for 6 weeks.  The prescribed radiotherapy dose will be 60 Gy in 2 Gy once-daily fraction size (total of 30 fractions)
Patients also receive cisplatin 40 mg/m2 IV on Days 1, 8, 15, 22, 29, and 36 of radiation therapy (6 doses for a total of 240 mg/m2).</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Intensity-modulated radiation therapy (IMRT)</intervention_name>
    <arm_group_label>Radiotherapy</arm_group_label>
    <arm_group_label>Radiotherapy, cisplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <arm_group_label>Radiotherapy, cisplatin</arm_group_label>
    <other_name>CACP, CDDP, CPDD, DDP, Neoplatin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient must have histologically confirmed p16 positive squamous cell carcinoma of
             the oropharynx (OPSCC).

          -  Patient must have undergone transoral resection of their T1-4a oropharynx primary to
             a negative margin, and a neck dissection(s).

          -  Patient's disease must be pathological N-stage positive.

          -  Patient's disease must show extracapsular spread (ECS) in their nodal metastasis
             verified by central pathologist's review.

          -  Patients with synchronous primaries are included.

          -  Patients with unknown primaries are included if the diagnosis of a primary site in
             the oropharynx is made during the surgery.

          -  Patients with recent excisional node biopsies/neck dissections are included if
             material is evaluable for extracapsular spread.

          -  Patient must be ≥ 21 years of age.

          -  ECOG performance status ≤ 2 (Karnofsky ≥60%).

          -  Patients must have normal organ and marrow function as defined below:

          -  leukocytes ≥3,000/mcL

          -  absolute neutrophil count ≥1,500/mcL

          -  platelets ≥100,000/mcL

          -  total bilirubin &lt;1.5 X upper normal institutional limit

          -  AST(SGOT)/ALT(SGPT) ≤2.5 X institutional upper limit of normal

          -  creatinine within normal institutional limits OR

          -  creatinine clearance ≥60 mL/min/1.73 m2 for patients with creatinine levels above
             institutional normal

          -  Patient (or legally authorized representative) must be able to understand and willing
             to sign a written informed consent document.

        Exclusion Criteria:

          -  Patient must not have pathologically N stage negative disease.

          -  Patient must not have outside nodal tissue from previous neck biopsy/neck dissections
             in which ECS cannot be confirmed or denied.

          -  Patient must not have a true unknown primary in which permanent section results are
             negative for malignancy in completely excised ipsilateral oropharyngeal tissue
             (palatine and lingual tonsil).

          -  Patient must not have distant metastatic disease at presentation.

          -  Patient must not have gross residual and/or microscopic disease present after surgery
             including re-resection(s), per the operative and pathology report.

          -  Patient must not have a history of prior invasive malignancy (except non-melanomatous
             skin cancer) unless disease free for a minimum of 3 years; noninvasive cancers (for
             example, carcinoma in situ of the oral cavity, larynx, breast or cervix are all
             permissible) are permitted even if diagnosed and treated &lt; 3 years ago.

          -  Patient must not have had previous systemic chemotherapy for the study cancer. (Note:
             prior chemotherapy for a different cancer is allowable).

          -  Patient must not be receiving any other investigational agents.

          -  Patient must not have had any prior radiotherapy to the region of the study cancer
             that would result in overlap of radiation therapy fields

          -  Patient must not have any life-threatening comorbid illnesses e.g. stroke with major
             sequelae or myocardial infarction/ unstable angina within the preceding 3 months or
             psychiatric illness/social situations that would limit compliance with study
             requirements.

          -  Patient must not be pregnant or breastfeeding.  If a woman of childbearing potential,
             patient must agree to use medically acceptable forms of contraception.

        Both men and women and members of all races and ethnic groups are eligible for this trial.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bruce Haughey, MBChB</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bruce Haughey, MBChB</last_name>
    <phone>314-362-0365</phone>
    <email>haugheyb@ent.wustl.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Casey Rowe, MS</last_name>
    <phone>314-362-8547</phone>
    <email>rowec@wudosis.wustl.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mayo Clinic Scottsdale</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259-5499</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - All Mayo Clinic Locations</last_name>
      <phone>507-538-7623</phone>
    </contact>
    <investigator>
      <last_name>Matthew Zarka, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kelly Curtis, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Samir Patel, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Hinni, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruce Haughey, MBChB</last_name>
      <phone>314-362-0365</phone>
      <email>haugheyb@ent.wustl.edu</email>
    </contact>
    <contact_backup>
      <last_name>Casey Rowe, MS</last_name>
      <phone>314-362-8547</phone>
      <email>rowec@wudosis.wustl.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Hiram Gay, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Wade Thorstad, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Douglas Adkins, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tanya Wildes, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Loren Michel, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>James Lewis, Jr., M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Samir El-Mofty, Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jason Diaz, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Parul Sinha, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Stadler, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ravindra Uppaluri, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Brian Nussenbaum, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Randal Paniello, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jason Rich, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bruce Haughey, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lanis Hall, M.D., M.P.H.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Timothy Pluard, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rebecca Chernock, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jay Piccirillo, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UT Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Baran Sumer, M.D.</last_name>
      <phone>214-648-2904</phone>
      <email>Baran.Sumer@UTSouthwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Baran Sumer, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joel Thibodeaux, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Randall Hughes, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Gerber, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matt Karpowicz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lucien Nedzi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Saad Khan, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>John Yordy, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Larry Myers, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>John Truelson, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joan Schiller, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Susie Chen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.siteman.wustl.edu</url>
    <description>Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine</description>
  </link>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 15, 2014</lastchanged_date>
  <firstreceived_date>September 13, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Oropharyngeal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
